Cymbalta News and Research

RSS
Cymbalta is a drug used to treat depression and peripheral neuropathy (pain, numbness, tingling, burning, or weakness in the hands or feet) that can occur with diabetes. It is also being studied in the treatment of peripheral neuropathy caused by certain anticancer drugs. Cymbalta increases the amount of certain chemicals in the brain that help relieve depression and pain. It is a type of serotonin and norepinephrine reuptake inhibitor. Also called duloxetine and duloxetine hydrochloride.
Finding better way to quantify neuropathy symptoms and treatment efficacy

Finding better way to quantify neuropathy symptoms and treatment efficacy

Functional MRI brain scan may help predict patient’s response to antidepressant therapy

Functional MRI brain scan may help predict patient’s response to antidepressant therapy

Depression drug can alleviate joint pain in postmenopausal women treated for breast cancer

Depression drug can alleviate joint pain in postmenopausal women treated for breast cancer

AVACEN Medical launches $2M campaign in response to positive outcomes of fibromyalgia study

AVACEN Medical launches $2M campaign in response to positive outcomes of fibromyalgia study

Breckenridge announces launch of Duloxetine Delayed-release Capsules

Breckenridge announces launch of Duloxetine Delayed-release Capsules

Actavis’ net revenue increases 40% to $2.66B in Q1 2014

Actavis’ net revenue increases 40% to $2.66B in Q1 2014

BDSI enrolls first patient in Clonidine Topical Gel Phase 3 trial for treatment of painful diabetic neuropathy

BDSI enrolls first patient in Clonidine Topical Gel Phase 3 trial for treatment of painful diabetic neuropathy

Duloxetine drug reduces painful chemotherapy-induced peripheral neuropathy in majority of patients

Duloxetine drug reduces painful chemotherapy-induced peripheral neuropathy in majority of patients

Tonix completes TNX-102 pharmacokinetic study on fibromyalgia syndrome

Tonix completes TNX-102 pharmacokinetic study on fibromyalgia syndrome

First-ever comprehensive study of species origins of nature-derived drugs

First-ever comprehensive study of species origins of nature-derived drugs

UTHealth to study BMS-820836 in Phase II trial for major depressive disorder

UTHealth to study BMS-820836 in Phase II trial for major depressive disorder

Health Canada approves Eli Lilly's Cymbalta for chronic low back pain treatment

Health Canada approves Eli Lilly's Cymbalta for chronic low back pain treatment

Depression drug appears effective in reducing pain associated with breast cancer treatment

Depression drug appears effective in reducing pain associated with breast cancer treatment

USFDA grants Sun Pharma tentative marketing approval for generic Cymbalta

USFDA grants Sun Pharma tentative marketing approval for generic Cymbalta

FDA grants Impax tentative approval for generic Cymbalta NDA

FDA grants Impax tentative approval for generic Cymbalta NDA

FDA approves Cymbalta for treatment of chronic musculoskeletal pain

FDA approves Cymbalta for treatment of chronic musculoskeletal pain

FDA Advisory Committee votes in favor of expanding pain indications for Eli Lilly's Cymbalta

FDA Advisory Committee votes in favor of expanding pain indications for Eli Lilly's Cymbalta

Euthymics Bioscience completes $24 million Series A financing

Euthymics Bioscience completes $24 million Series A financing

Combination therapy for severe depression

Combination therapy for severe depression

TheraQuest launches new analgesic product pipeline

TheraQuest launches new analgesic product pipeline